NCT07222748进行中（未招募）3 期
A Phase 3, Randomized, Double-blind, Comparator- and Placebo-controlled Study to Evaluate the Safety and Efficacy of TLC590 for Postsurgical Pain Management Following Bunionectomy
TLC Biopharmaceuticals, Inc.4 个研究点 分布在 1 个国家目标入组 304 人开始时间: 2025年11月17日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 304
- 试验地点
- 4
- 主要终点
- Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores Through 72 Hours Postsurgery (AUC0-72), Compared with Saline Placebo.
研究概览
简要总结
This is a Phase 3, randomized, double-blind, comparator- and placebo-controlled study to evaluate analgesic efficacy and safety of TLC590 via local infiltration in adult subjects following bunionectomy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Able and willing to provide written informed consent.
- •Male or female aged 18 years or older (inclusive).
- •Scheduled to undergo a primary unilateral, transpositional first metatarsal bunionectomy with osteotomy and internal fixation under regional anesthesia.
- •ASA Physical Status Classification of 1 or
- •Male subjects must be either biologically or surgically sterile or commit to the use of a reliable method of birth control (must agree to use double-barrier contraception in the event of sexual activity) or be practicing abstinence.
- •Female subjects are eligible only if not pregnant, not lactating, not planning to become pregnant during the study, or committing to the use of a highly effective method of birth control.
- •BMI >18 ~ ≤39 kg/m2, with a minimum weight of 50 kg.
排除标准
- •An abnormal clinical laboratory test value.
- •Evidence of a clinically significant abnormal 12-lead ECG.
- •History of orthostatic hypotension, syncope, or other syncopal attacks.
- •History or any clinical manifestation of significant renal, hepatic, gastrointestinal, cardiovascular, metabolic, neurologic, psychiatric, or other conditions that have been assessed by the Investigator to make the subject unsuitable for participation in the study.
- •History of seizures or taking anticonvulsants.
- •History of cardiac arrhythmia or taking Class III antiarrhythmic drugs.
- •History of sleep apnea or at-home CPAP treatment.
- •History of hypersensitivity to ropivacaine, bupivacaine, any other amide-type local anesthetic, or any other trial-required medications.
- •History of severe or refractory PONV due to other etiologies, including, but not limited to gastric outlet obstruction, hypercalcemia, or active peptic ulcer, deemed clinically significant by the Investigator.
- •Any lifetime history of a suicidal attempt or any suicidal behavior.
- •History or positive test results of HIV, HCV, or HBV.
- •History or current report of substance abuse including illicit drug abuse and/or alcohol abuse.
- •Positive results on the urine drug screen or alcohol breath test.
- •Pre-existing concurrent acute, or chronic painful restrictive/physical condition that may confound postoperative pain assessments or is expected to require analgesic treatment during the study.
- •Has known or suspected daily use of opioids for longer than 4 days per week within 6 months.
- •Use of daily analgesics for longer than 4 days per week for a chronically painful condition.
- •Is receiving oxygen therapy.
- •Use of any of the pre-specified medications prior to the study surgical procedure or as specified.
- •Malignancy in the past 2 years, except for non-metastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.
- •Personal or family history of malignant hyperthermia.
研究组 & 干预措施
Liposomal Bupivacaine
Active Comparator
干预措施: Liposomal Bupivacaine (Drug)
TLC590
Experimental
干预措施: TLC590 (Drug)
Saline Placebo
Placebo Comparator
干预措施: Saline Placebo (Drug)
结局指标
主要结局
Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores Through 72 Hours Postsurgery (AUC0-72), Compared with Saline Placebo.
时间窗: 72 hours
Pain intensity is measured using an 11-point Numeric Rating Scale (NRS) (0-10), where 0 represents "no pain" and 10 represents "worst pain imaginable", and higher scores indicate worse pain.
Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores Through 72 Hours Postsurgery (AUC0-72), Compared with Saline Placebo.
时间窗: 72 hours
Pain intensity is measured using an 11-point Numeric Rating Scale (NRS) (0-10), where 0 represents "no pain" and 10 represents "worst pain imaginable", and higher scores indicate worse pain.
次要结局
- Proportion of subjects who are opioid-free for TLC590 compared with Saline Placebo.(72 hours)
- Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores Through 72 Hours Postsurgery (AUC0-72), Compared with Bupivacaine Liposome.(72 hours)
- Mean Total Postoperative Opioid Consumption for TLC590 Compared with Saline Placebo(72 hours)
- Proportion of subjects who are opioid-free for TLC590 compared with Bupivacaine Liposome.(72 hours)
- Mean Total Postoperative Opioid Consumption for TLC590 Compared with Bupivacaine Liposome.(72 hours)
- Proportion of subjects who are opioid-free for TLC590 compared with Saline Placebo.(72 hours)
- Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores Through 72 Hours Postsurgery (AUC0-72), Compared with Bupivacaine Liposome.(72 hours)
- Mean Total Postoperative Opioid Consumption for TLC590 Compared with Saline Placebo(72 hours)
- Proportion of subjects who are opioid-free for TLC590 compared with Bupivacaine Liposome.(72 hours)
- Mean Total Postoperative Opioid Consumption for TLC590 Compared with Bupivacaine Liposome.(72 hours)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
3 期
A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell CarcinomaEsophageal Squamous Cell Carcinoma (ESCC)NCT03957590BeiGene370
已完成
3 期
JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic DermatitisAtopic DermatitisNCT03796676Pfizer287
招募中
3 期
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)Psychosis Associated With Alzheimer's DiseaseNCT06126224Karuna Therapeutics, Inc., a Bristol Myers Squibb company500
招募中
3 期
A study to compare the effectiveness and safety of Atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal functionOther acute kidney failure,CTRI/2022/06/043396Chinook Therapeutics320
进行中（未招募）
3 期
A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein CholesterolPure hypercholesterolemia,CTRI/2012/09/003013Genzyme India480